Skip to main content
OpenTrials
Completed

NCT Number: NCT01846273

Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)

This study compared the effect of ranibizumab administered as monotherapy versus ranibizumab administered in combination with verteporfin photodynamic therapy (PDT) on visual acuity in patients with symptomatic macular polypoidal choroidal vasculopathy (PCV). The results of this study provided long-term safety and efficacy data used to generate further guidance on the management of patients with PCV.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age-Related Macular Degeneration Choroid Diseases Choroidal Neovascularization Eye Diseases Macular Degeneration Metaplasia Neovascularization, Pathologic Pathologic Processes Pathological Conditions, Signs and Symptoms Polypoidal Choroidal Vasculopathy Retinal Degeneration Retinal Diseases Uveal Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Novartis Investigative Site, Hong Kong

Loading trial locations.

About this study

Patients were randomized to the study in 2 treatment groups: ranibizumab + vPDT combination therapy, and ranibizumab monotherapy. Based on the results of the primary analysis at Month 12, patients still in the ranibizumab monotherapy group at the time of the switch cut-off time point were switched to the ranibizumab + vPDT combination therapy group until study exit. A total of 168 and 154 patients were included in the ranibizumab + vPDT combined therapy and ranibizumab monotherapy groups, respectively for the FAS (Month 12 analysis). However, the safety set included 172 and 149 patients, respectively. Four patients in the combination therapy group never took vPDT . Among them, 1 patient actually received verteporfin injection but no laser injection. Thus a total of 3 patients (4-1) in the combination therapy group did not take the actual full vPDT treatment. Additionally, 7 patients in the monotherapy group received vPDT and 1 patient from the monotherapy group did not receive ranibizumab treatment. Considering the above numbers, safety set included 172 patients (i.e., 168-3+7) in the ranibizumab + vPDT combination therapy group and 149 patients (i.e., 154-7+3-1) in the ranibizumab monotherapy group for Month 12 analysis. For the Month 24 safety analysis, the 14 patients in the ranibizumab monotherapy group who were switched to ranibizumab +vPDT combination therapy group were analyzed as a separate group, ie, ranibizumab 0.5 mg + vPDT (switched).

.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Confirmed diagnosis of symptomatic macular PCV in the study eye
  • A qualifying vision score at study entry
  • A qualifying lesion size in the study eye at study entry

Exclusion criteria

  • Active inflammation or infection in the study eye
  • Uncontrolled intraocular pressure in the stuy eye
  • Ocular condition in the study eye which may impact vision and confound study outcomes
  • Prior treatment of the study eye with anti-VEGF therapy, verteporfin PDT, other laser and surgical interventions, intraocular corticosteroids

Treatment and study plan

ranibizumab

Drug

Intravitreal injection of 0.5 mg ranibizumab

Other names: Lucentis

Verteporfin PDT

Drug

Infusion of 30 ml verteporfin in 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)

Sham PDT

Drug

Infusion of 30 ml 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)

Primary outcomes

  1. Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 - Study Eye

    Time frame: Baseline, Month 12

    Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts. The BCVA score is the number of letters read correctly by the patient, hence an increase in score indicates improvement in acuity.

  2. Number of Patients With Complete Polyp Regression From Baseline at Month 12 - Study Eye

    Time frame: Baseline, Month 12

    Polyp regression was based on the Indocyanine green angiography (ICGA) assessment by the Central Reading Center (CRC). A patient was considered to have complete polyp regression if the presence of polyps, as assessed by CRC, had value "No." Polyp regression which may lead to disease stabilization and consequently better vision.

Secondary outcomes

  1. Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) at Month 24 - Study Eye

    Time frame: Baseline, Month 24

    Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a starting test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient, hence an increase in score indicates improvement in acuity.

  2. Percentage of Patients With BCVA (Letters) Change From Baseline at Month 24 - Study Eye

    Time frame: Baseline, Month 24

    BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20.

  3. Maintenance of BCVA (Within 5 Letter Change) at Month 12 and 24 Compared to BCVA at the Time Point of First Ranibizumab Treatment Interruption

    Time frame: Month 3, Month 12, Month 24

    Best Corrected Visual Acuity (BCVA) was assessed using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a starting test distance of 4 meters.

  4. Change in BCVA at Month 12 and 24 Compared to the Time Point of First Ranibizumab Treatment Interruption

    Time frame: Month 3, Month 12, Month 24

    Best Corrected Visual Acuity (BCVA) was assessed using best correction determined from protocol refraction at a starting test distance of 4 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a starting test distance of 4 meters.

  5. Percentage of Patients With Complete Polyp Regression at Months 6 and 24 - Study Eye

    Time frame: Month 6, Month 24

    Polyp regression was based on the Indocyanine green angiography (ICGA) assessment by the Central Reading Center (CRC). A patient was considered to have complete polyp regression if the presence of polyps, as assessed by CRC, had value "No." Polyp regression which may lead to disease stabilization and consequently better vision.

  6. Percentage of Patients With Presence of Leakage at Month 6, Month 12 and Month 24 - Study Eye

    Time frame: Month 6, Month 12 and Month 24

    Presence of lesion leakage was based on Fluorescein Angiography (FA) as assessed by the Central Reading Center (CRC). The presence of leakage may lead to disease progression and worsening vision.

  7. Mean Change From Baseline in Investigator-Assessed Central Subfield Retinal Thickness (CSFT) at Month 24 - Study Eye

    Time frame: Baseline, Month 24

    The thickness of the retina was measured using Spectral Domain (SD) optical coherence tomography (OCT) equipment (SD-OCT) and reported as a difference, in micrometers. A negative number indicates a reduction in thickness, whereas a positive number indicates an increase. An increase in thickness may indicate a progression of the underlying disease.

  8. Total Number of Ranibizumab Injections Received in the Study Eye Prior to Month 12

    Time frame: Baseline, Month 12

  9. Total Number of Verteporfin/Sham PDT Injections Received in the Study Eye Prior to Month 12

    Time frame: Baseline, Month 12

  10. Total Number of Ranibizumab Injections Received in the Study Eye Prior to Month 24

    Time frame: Baseline, Month 24

  11. Total Number of Verteporfin/Sham PDT Injections Received in the Study Eye Prior to Month 24

    Time frame: Baseline, Month 24

  12. Total Number of Ranibizumab Injections Received in the Study Eye From Month 3 to Month 12

    Time frame: Month 3, Month 12

  13. Total Number of Ranibizumab Injections Received in the Study Eye From Month 3 to Month 24

    Time frame: Month 3, Month 24

  14. Mean Change From Baseline in Composite Scores, National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25) at Months 3, 12 and 24

    Time frame: Baseline, Month 3, Month 12, Month 24

    The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) was used to measure a patient's subjective assessment of vision-related quality of life at Months 3, 12 and 24. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. The scores on the subscales were added together for a total score, which ranged from 0 to 100. A higher score indicated poorer function.

  15. Number of Ocular Adverse Events of the Study Eye Regardless of Study Drug Relationship up to Month 24, Any Primary System Organ Class

    Time frame: Up to Month 24

    Reported categorically: Mild, Moderate, Severe

  16. Number of Non-Ocular Adverse Events of the Study Eye Regardless of Study Drug Relationship up to Month 24, Any Primary System Organ Class

    Time frame: Up to Month 24

    Reported categorically: Mild, Moderate, Severe

Sponsors and collaborators

Lead sponsor

Novartis Pharmaceuticals

Industry

Registry information

Official study title

A 24-month, Phase IV, Randomized, Double Masked, Multi-center Study of Ranibizumab Monotherapy or Ranibizumab in Combination With Verteporfin Photodynamic Therapy on Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy

Acronym: EVEREST II

Important dates

Study start
2013
Primary completion
2016
Study completion
2017
First posted
May 3, 2013
Registry last updated
Jun 7, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.